Cell & Gene Therapy: The future of medicine attracts major M&A activity
The Life Sciences sector has recently had the spotlight shining upon it, as a result of the global COVID-19 pandemic, and we have seen extensive investment and redeployment and refocusing of resources seeking appropriate diagnostics, treatments and vaccines. But while all this is happening, a quiet revolution continued to brim over in the pharma world which may produce long term benefits – that of Cell and Gene Therapy (CGT).
CGT has been seen as the ‘future’ of medicine for many years and now we are closer than ever to that future becoming a reality. As such, innovative CGT-based tech and businesses have become the new talk of the pharma town, according to finnCap Group’s Life Sciences analysts, our colleagues writing in the latest Life Sciences Quarterly Sector Note.